Home > Insider Trading > Cit Group Inc > Profile

Cit Group Inc (CIT)

Related Insiders

Seymour Sternberg, Director, 2012-05-16
S Laura Unger, Director, 2012-05-16
J Peter Tobin, Director, 2012-05-16
J Michael Embler, Director, 2012-05-14
Brad R. Oates, Director, 2012-05-14
M David Moffett, Director, 2012-05-14
M Marianne Parrs, Director, 2012-05-14
M William Freeman, Director, 2012-05-14
A John Thain, Chairman & Ceo, 2012-05-01
Andrew Brandman, Exec. Vice President & Cao, 2012-04-26
Jeffrey C Knittel, President, Transportation Fin., 2012-02-21
G Ron Arrington, President, Vendor Finance, 2012-02-21
Lisa Polsky, Exec Vp & Chief Risk Officer, 2012-02-21
T Scott Parker, Evp & Chief Financial Officer, 2012-02-21
L James Hudak, Co-President, Corp. Finance, 2012-02-21
J Robert Ingato, Exec Vp And General Counsel, 2012-02-21
Carol Hayles, Svp & Controller, 2012-02-21
F John Daly, President, Trade Finance, 2012-02-21
Peter Connolly, Co-President, Corp. Finance, 2012-02-21
Lisa Zonino, Executive Vice President, 2012-02-21
Gerald Rosenfeld, Director, 2012-02-08
Nelson Chai, Exec Vp, Cao, Head Of Strategy, 2012-02-03
J. Raymond Quinlan, Evp - Banking, 2012-02-03
D Margaret Tutwiler, Evp, Marketing & Communication, 2012-02-03
R John Ryan, Director, 2011-07-28
T Alexander Mason, Officer, 2009-12-14
M Joseph Leone, Officer, 2009-12-14
J. Kelley Gipson, Officer, 2009-12-14
J Nancy Foster, Officer, 2009-12-14
J James Duffy, Officer, 2009-12-14
M Lois Vandeusen, Director, 2009-12-14
H Christopher Shays, Director, 2009-12-14
M Jeffrey Peek, Director, 2009-12-14
M Susan Lyne, Director, 2009-05-14
A Michael Carpenter, Director, 2009-05-14

Show More Insiders (35)

Hedge Fund Holdings See All

Showing:

Sorted by:

No.	Hedge Fund	Shares	Value (x$1000)	Activity	% Port
1.)	Centerbridge Partners Mark T. Gallogly	8,847,021	$308,496		26.43%
2.)	Avenue Capital Marc Lasry	1,798,780	$62,723		12.96%
3.)	Fairholme (Fairx) Bruce Berkowitz	18,616,669	$649,163	-4%	10.61%
4.)	Litespeed Management Jamie Zimmerman	612,500	$21,358	-24%	8.29%
5.)	North Run Capital Thomas Ellis And Todd Hammer	1,300,000	$45,331		6.09%

Insider Trading: Purchases See All

Insider	Price	Amount	Relationship	Remaning Holdings	Date	Form 4
Thain	$37.73	200	Director	318762.5349	2012-04-30	Filing
Thain	$37.65	600	Director	313646.5349	2012-04-30	Filing
Thain	$37.735	600	Director	313046.5349	2012-04-30	Filing
Thain	$37.83	674	Director	312446.5349	2012-04-30	Filing
Thain	$37.585	700	Director	311772.5349	2012-04-30	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Gipson	$4.18	55	Officer	32842	2008-12-24	Filing

News See All

Hedge Funds News : John Paulson, Mini-Madoff, Maverick Capital

Posted at April 18th, 2012 in Hedge Funds

John Paulson, the hedge fund manager who made billions betting against the U.S. mortgage market in 2007, has found something new to bet against. Paulson told investors on a recent conference call that...

Hedge Fund News : T. Boone Pickens, Warren Buffett, Jim Chanos

Posted at April 13th, 2012 in Hedge Funds

Citadel, run by Ken Griffin out of Chicago, reported $115.2 billion of regulatory assets in a March 30 filing with the U.S. Securities and Exchange Commission, compared with $12.6 billion of net assets...

Pay for Hedge Fund Managers Falls 35%, Top 6 Average Just $1.7B

Posted at March 30th, 2012 in Hedge Fund Analysis The Smart Set

"Compensation for the highest-paid U.S. hedge-fund managers plunged 35 percent in 2011 to $14.4 billion after the European sovereign debt crisis pushed the industry to its second-worst year ever," reports...

Do Computerized Trading Platforms Yield an Unfair Advantage?

Posted at March 24th, 2012 in The Smart Set

"Federal securities regulators are examining whether some sophisticated, rapid-fire trading firms have used their close links to computerized stock exchanges to gain an unfair advantage over other investors...

Why Do Hedge Funds Love Pfizer $PFE?

Posted at March 15th, 2012 in Dividend Stocks Hedge Funds

Japan is not alone in undergoing a “lost decade.” Investors who bought shares of large cap pharmaceutical companies ten years ago have seen an overall price decline or flat performance from 2001 to...